Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine:
”New NEJM trial: Apixaban vs Rivaroxaban in acute VTE
Clinically relevant bleeding:
Apixaban 3.3%
Rivaroxaban 7.1%
RR 0.46
- Similar efficacy for recurrent VTE
- Significantly lower bleeding with apixaban
However, an important limitation: Cancer-associated thrombosis patients were excluded from the trial.
So there is no direct evidence in oncology patients. Still, in daily oncology practice — especially in patients with higher bleeding risk — this signal may be worth keeping in mind when choosing between DOACs.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine

Stay updated on all scientific advances with Hemostasis Today.
-
Sep 14, 2026, 16:14Susanne Lager: Isthmin-2 Emerges as an Early Predictor of Pregnancy Complications
-
Sep 14, 2026, 15:53Leonard Valentino: Advancing a New Model of Patient-Led Research
-
Sep 14, 2026, 15:48Adishwar Rao: LAAC vs Oral Anticoagulation in Atrial Fibrillation
-
Sep 14, 2026, 15:36Lesley Van Wyk: Hemolytic Anemia Quick Revision – Tips and Tricks
-
Sep 14, 2026, 15:35Maha Othman: ISTH-BAT Reference Ranges Validated Across Five Continents in Children
-
Sep 14, 2026, 15:30Umberto Pensato։ Left Ventricular Dysfunction and DOAC Benefit in ESUS
-
Sep 14, 2026, 15:22Meral Kayikcioglu: Why Do Women and Men Differ in LDL-C Management?
-
Sep 14, 2026, 15:22James Crowley: The Complex Role of CRP in Cardiovascular Risk and Atherosclerosis
-
Sep 14, 2026, 15:16Factor XIII Deficiency An Often-Missed Bleeding Disorder